ClinicalTrials.gg

Program

Picibanil

Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Neoplasms · Lymphatic Abnormalities, led by Protara Therapeutics.

Furthest: phase 3, since Mar 13, 20265 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Protara Therapeutics53 open or runningphase 3since Mar 13, 2026Oct 7, 2021Dec 2026phase 2 · NCT05871970

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2021First studies: 2 phase 1 studies in Non-Muscle Invasive Bladder NeoplasmsFirst studyNCT05085990, NCT05085977
  2. May 11, 2023Phase 2 study in Lymphatic AbnormalitiesNCT05871970 · 38 planned · United States
  3. Jun 29, 2023Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT05951179 · 131 planned · United States, Argentina, Brazil and more
  4. Mar 13, 2026Phase 3 study in NeoplasmsPhase 3 reachedNCT07480356 · 284 planned · United States, Ukraine

Ahead

  1. Dec 2026Primary completion: phase 2 study in Lymphatic AbnormalitiesNCT05871970
  2. Apr 2028Primary completion: phase 3 study in NeoplasmsNCT07480356
  3. Oct 2031Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT05951179

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07480356Neoplasms · United States, Ukraine3RecruitingApr 2028284
NCT05951179Non-Muscle Invasive Bladder Neoplasms · United States, Argentina, Brazil and more2RecruitingOct 2031131
NCT05871970Lymphatic Abnormalities · United States2RecruitingDec 202638
NCT05085990Non-Muscle Invasive Bladder Neoplasms · United States1CompletedSep 12, 202410
NCT05085977Non-Muscle Invasive Bladder Neoplasms · United States, Moldova, Republic of, Romania and more1CompletedSep 3, 202412

How it is read

Names in the registry

  • “TARA-002”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.